THDB(SH:600867) Cai Jing Wang·2025-10-09 07:40Core Viewpoint - Tonghua Dongbao held a performance briefing for the first half of 2025, highlighting significant advancements in clinical trials and sales growth in insulin products [1] Group 1: Clinical Trials and Product Development - The injection THDBH120 for weight loss indications has completed its first patient dosing in a Phase II clinical trial as of January 2025, showing good safety, tolerability, and positive efficacy trends [1] - The company's insulin formulations are still in preclinical research, with future developments to be disclosed according to relevant regulations [1] Group 2: Domestic Market Performance - In the first half of 2025, the sales of insulin analogs in the domestic market achieved over 200% year-on-year growth [1] - The company plans to leverage the new round of centralized procurement to significantly boost the sales of insulin analogs and expand market share [1] Group 3: International Market Developments - The U.S. BLA for Aspart insulin has been accepted by the FDA, with ongoing efforts to advance the BLA submissions for Glargine and Lispro insulins [1] - Registration preparation and application work for insulin analogs in Europe and various developing countries are progressing in an orderly manner [1]